Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs HCA Health Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while HCA Health Inc trades at $406.59 (market cap $90.20B). The key difference: HCA Health Inc pays a 0.77% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKQ | HCA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $545.13 |
52-Week Low | $91.86 | $334.32 |
Market Cap | — | $90.20B |
Enterprise Value | — | $139.10B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
HCA Healthcare trades at $406.59, down 0.59% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $7.37. Revenue growth is robust, reaching $75.60 billion in 2025, while valuation metrics like a P/E of 14.01 and EV/EBITDA of 8.88 suggest relative attractiveness. Recent news highlights capacity expansion and gene therapy advancements.
The outlook for HCA remains positive, supported by earnings momentum and strategic investments, but risks include high debt levels and regulatory pressures. Analyst consensus is bullish with a $486.10 price target, indicating ~20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
